Results 181 to 190 of about 70,554 (222)
Signal mining and analysis of influencing factors for adverse events of Nivolumab and Cetuximab in the treatment of head and neck cancer based on the US FAERS database. [PDF]
Front ImmunolTang Y +7 more
europepmc +1 more source
Tailored strategies for improved control of CAR-T cells in multiple myeloma. [PDF]
Front ImmunolBielowski A +7 more
europepmc +1 more source
Nanomedicine as an opportunity for equity achievements through cost-reduction in public healthcare for head and neck cancer treatment in Brazil. [PDF]
BMC Health Serv Resde Andrade LM, Ladeira LO.
europepmc +1 more source
Patient-derived xenograft models of Fanconi anemia-associated head and neck cancer identify personalized therapeutic strategies. [PDF]
J Clin InvestGrandis JR +25 more
europepmc +1 more source
Triplet chemotherapy combined with anti Epidermal Growth Factor Receptor treatment in RAS wild-type colorectal cancer: a network metanalysis. [PDF]
OncologistDi Nardo P +14 more
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Nature Reviews Drug Discovery, 2005
Cetuximab (Erbitux; ImClone Systems/Bristol-Myers Squibb) is a monoclonal antibody that binds to the epidermal growth factor receptor, which is important in the growth of many cancers. In February 2004, it was granted accelerated approval by the US FDA for the treatment of metastatic colorectal cancer on the basis of tumour response rates in Phase II ...
Richard Goldberg
exaly +5 more sources
Cetuximab (Erbitux; ImClone Systems/Bristol-Myers Squibb) is a monoclonal antibody that binds to the epidermal growth factor receptor, which is important in the growth of many cancers. In February 2004, it was granted accelerated approval by the US FDA for the treatment of metastatic colorectal cancer on the basis of tumour response rates in Phase II ...
Richard Goldberg
exaly +5 more sources